The Stephenson Cancer Center (SCC) at the University of Oklahoma Health Sciences Center (OUHSC) is applying to become a Lead Academic Site in the National Clinical Trials Network (NCTN). The SCC has been a leading accrual site for the NCTN, averaging 205 patients enrolled annually on CTEP trials over the past six years. Leading this effort are SCC Director Robert Mannel, MD (Contact PI) and Associate Director for Clinical Research Scott McMeekin, MD (PI). Both PIs have an outstanding record of scientific and administrative leadership. Along with the grant Investigators, they clearly demonstrate an ability and commitment to function as a coordinated research team and work effectively with components across the NCTN. The SCC is currently a primary institution for Gynecologic Oncology Group (GOG), Radiation Therapy Oncology Group (RTOG), and Alliance (previously CALGB). In addition, it registers patients on ECOG and SWOG trials through the CTSU mechanism and actively participates with ACRIN. The SCC has been a leader for the past decade in the design and conduct of CTEP trials that have defined the standard of care for numerous malignancies. Over the past six years the SCC enrolled 1,232 patients on CTEP therapeutic trials, including an all-time institutional high of 238 patients in 2012 (with projecte enrollment of 258 in 2013), making it a national leader in accrual for the NCTN. As a Lead Academic Site the SCC will continue to work with Network coordinating centers to be a leader in the design and conduct of NCTN trials for newly-developed therapies, including multi-modality treatments, combinations of novel agents, molecularity-based treatments, advanced imaging approaches, quality biospecimen acquisition and translational research. It will accomplish this goal within the context of providing high-quality cancer care and access to NCTN clinical trials for Oklahomans, especially for the state's special populations that experience significantly high rates of cancer health disparities. As the state's only academic cancer center, the SCC plays a crucial role in providing all Oklahomans access to NCTN clinical trials, definitively evaluating novel therapies, raising the standard of care and easing the burden of cancer for the region.
This proposal is directly relevant to public health. As a Lead Academic Site in the NCTN, the SCC will directly contribute to the design and conduct of definitive, randomized, early and late Phase clinical trials for newly-developed therapies, including multi-modality treatments, combinations of novel agents, molecularity- based treatments, and advanced imaging approaches. The ultimate goal is to improve the health of all populations, with an emphasis on special populations such as American Indians.
|Jandial, Danielle A; Brady, William E; Howell, Stephen B et al. (2017) A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 145:236-242|
|Ng, Chaan S; Zhang, Zheng; Lee, Susanna I et al. (2017) CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study. Clin Cancer Res 23:3684-3691|
|Grabosch, Shannon; Tseng, George; Edwards, Robert P et al. (2017) Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 146:137-145|
|Oliver, Kate E; Brady, William E; Birrer, Michael et al. (2017) An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol 147:243-249|
|Thaker, Premal H; Brady, William E; Lankes, Heather A et al. (2017) A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal Gynecol Oncol 147:283-290|
|Jeske, Yvette W; Ali, Shamshad; Byron, Sara A et al. (2017) FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 145:366-373|
|von Gruenigen, Vivian E; Huang, Helen Q; Beumer, Jan H et al. (2017) Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. Gynecol Oncol 144:459-467|
|Winder, Abigail D; Maniar, Kruti P; Wei, Jian-Jun et al. (2017) Synuclein-? in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. Cancer 123:1144-1155|
|Creasman, William T; Ali, Shamshad; Mutch, David G et al. (2017) Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol. Gynecol Oncol 145:519-525|
|Devor, Eric J; Miecznikowski, Jeffrey; Schickling, Brandon M et al. (2017) Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 147:648-653|
Showing the most recent 10 out of 42 publications